



CHRONIX BIOMEDICAL APPOINTS INDUSTRY VETERAN PAUL E. FREIMAN AS CHAIRMAN

-Broad Expertise will Help Advance Tests Based on Serum DNA for Early Detection and Management of Cancer-

San Jose, California, July 15, 2009 – Chronix Biomedical, an innovator developing blood tests based on serum DNA for the early detection and management of cancer, today announced that Paul E. Freiman has been appointed Chairman of the Board of Directors. Mr. Freiman, the former CEO of Syntex Corporation and Neurobiological Technologies, Inc., brings Chronix a wealth of pharmaceutical and biotechnology experience from his more than 30 years of successful industry leadership.

“Access to routine tests that can identify cancer at an early stage is high on the wish lists of many oncologists and now Chronix has the capability to make this possible,” said Mr. Freiman. “I see the future of excellent health care treatment as dependent on personalized medicine. Chronix’s technology, which identifies critical molecular diagnostic markers, will facilitate achievement of this goal. I look forward to helping to advance this important technology as the company seeks partners for further development and commercialization.”

Chronix has developed technology that makes it possible to diagnose cancer before symptoms appear, and it does so using simple blood tests that can be easily integrated into routine medical practice. Chronix’s innovative blood tests work by capturing information contained in DNA released into the blood stream by damaged and dying cells. This circulating DNA provides a window into ongoing changes in the genome associated with disease, changes that can identify a disease process at its earliest stages and help track response to treatment. The Chronix approach has recently been validated in a number of peer-reviewed articles.

As former Chairman and Chief Executive Officer of Syntex Corporation, Mr. Freiman is credited with much of the marketing success of Syntex’s blockbuster product, Naprosyn®, and was responsible for moving the product to over-the-counter status, where it is marketed as Aleve®. He also was instrumental in the sale of Syntex to Roche Holdings for \$5.3 billion.

“Paul Freiman assuming the Chairman position at Chronix is a testament to the potential of our revolutionary serum DNA-based technology to transform the early diagnosis and management of cancer,” said Howard Urnovitz, Ph.D., Chief Executive Officer of Chronix. “Paul’s impressive record of biomedical industry leadership spans pharmaceuticals, diagnostics, biologics and public advocacy. We are fortunate to have the benefit of his broad experience and strategic counsel as we advance our technology through clinical validation toward commercialization.”

More recently, Mr. Freiman was President and Chief Executive Officer of Neurobiological Technologies, Inc. He also has extensive board experience, currently serving as Chairman of the Board of Penwest Pharmaceuticals Co., while also serving on the boards of Otsuka America Pharmaceuticals, Inc., NeoPharm Inc., and NovaBay Pharmaceuticals, Inc. Formerly, Mr. Freiman was Chairman of the Pharmaceutical Research and Manufacturers Association of America (PhRMA) and has chaired a number of key PhRMA committees. He holds a B.S. degree from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University.

About Chronix Biomedical

Chronix Biomedical is pioneering a breakthrough approach to the diagnosis and management of chronic diseases and cancer. It has developed proprietary technology that measures and categorizes DNA sequences circulating in the serum that are associated with specific changes in disease and health status. Using advanced genome analysis methodology, proprietary data tools and disease-specific databases, Chronix has demonstrated the utility of its diagnostic and prognostic approach in a chronic neurologic disease and in multiple myeloma. It currently is conducting studies in other cancers. The company plans to collaborate with a variety of partners to develop and market its serum DNA-based assays that have the potential to transform the management of a broad range of cancers and other conditions. Chronix is headquartered in San Jose, California and has research facilities in Germany. www.chronixbiomedical.com